drug

upadacitinib tartrate ER

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $6.0B

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rheumatoid arthritis and 14 investigational indications.

indications

investigational

IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(19)

approval · 19

view all 19 catalysts →

News(0)

no news has mentioned this drug yet

brand

Rinvoq

generic

upadacitinib tartrate

MOA

12.1 Mechanism of Action Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) which modulate intracellular activity including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In a cell-free isolated enzyme assay, upadacitinib had greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2. In human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

indication

Vitiligo

phase

marketed

approved

2019-08-16

upadacitinib tartrate ER

indications

all catalysts(19)

News(0)

comments(0)

Report a data issue

Patent cliff

patents (74)

FDA exclusivities (13)

🐶 often sniffed alongside

Trials studying upadacitinib tartrate ER